The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Amarantus In-licenses Levadopa-induced Dyskinesia Phase 2b-ready Eltoprazine from PGI Drug Discovery


(January 15, 2014) - Amarantus Bioscience Holdings, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, announced that it has completed the in-licensure of Eltoprazine from PGI Drug Discovery LLC. Amarantus expects to initiate a Phase 2b clinical trial for the treatment of Levadopa-Induced Dyskinesia associated with Parkinson's Disease in 2014 with Eltoprazine. Read more...



Article Archive

back